An FFG-funded consortium of Austrian research groups from the University of Vienna, MedUni Vienna and Technikum Wien together with company partner DOC Medikus GmbH has developed an innovative bioanalytical test system for radiopharmaceutical drug candidates for cancer diagnosis and therapy. It does not require any animal testing at all and enables automated, fast and highly precise analyses. The new method was presented in detail in the renowned Journal of Nuclear Medicine.

Gases used in anaesthesia are potent greenhouse gases, and their total global impact has not previously been known. A study published in The Lancet Planetary Health led by Lund University shows that greenhouse gas emissions from anaesthetic gases have decreased by 27% over the last ten years. By swapping out the anaesthetic gas with the highest climate impact, the climate impact of anaesthetic gases could have been reduced by a further 69%.

An experimental drug appears to reduce the risk of Alzheimer’s-related dementia in people destined to develop the disease in their 30s, 40s or 50s, according to the results of a study led by the Knight Family Dominantly Inherited Alzheimer Network-Trials Unit (DIAN-TU), which is based at Washington University School of Medicine in St. Louis. The findings suggest – for the first time in a clinical trial – that early treatment to remove amyloid plaques from the brain many years before symptoms arise can delay the onset of Alzheimer’s dementia.

A recent study conducted by researchers from Arizona State University has uncovered alarming levels of Fusarium mycotoxins in illicit cannabis samples seized in Arizona and California. The study found that 16% of the 118 samples tested positive for harmful mycotoxins, posing potential health risks to consumers. This groundbreaking research highlights the unregulated and dangerous nature of black-market cannabis.